"Cocktail" approaches and strategies in drug development: valuable tool or flawed science?
about
Predicting in vivo drug interactions from in vitro drug discovery data.Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamicsUse of cassette dosing in sandwich-cultured rat and human hepatocytes to identify drugs that inhibit bile acid transport.Effects of long-term smoking on the activity and mRNA expression of CYP isozymes in rats.Effects of schizonepetin on activity and mRNA expression of cytochrome p450 enzymes in rats.Neuroprotection by neuregulin-1 in a rat model of permanent focal cerebral ischemiaPharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check.Cytochromes P450: a structure-based summary of biotransformations using representative substrates.Cytochrome P450 variations in different ethnic populations.Impact of Tetrahydropalmatine on the Pharmacokinetics of Probe Drugs for CYP1A2, 2D6 and 3A Isoenzymes in Beagle Dogs.Predicting transporter-mediated drug interactions: Commentary on: "Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin and rosuvastatin" and "Validation of a microdose probe drug cocktail for clinicEvaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail.Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.Buspirone, fexofenadine, and omeprazole: quantification of probe drugs and their metabolites in human plasma.A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.Enhancing the mechanical stability of proteins through a cocktail approach.In-vitro and in-vivo evaluations of cytochrome P450 1A2 interactions with nuciferine.Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric?The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study).Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity.Effect of commercial Rhodiola rosea on CYP enzyme activity in humans.Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers.Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1'-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry.Cocktail approach for in vivo phenotyping of 5 major CYP450 isoenzymes: development of an effective sampling, extraction, and analytical procedure and pilot study with comparative genotyping.The effect of lycopene on cytochrome P450 isoenzymes and P-glycoprotein by using human liver microsomes and Caco-2 cell monolayer model.A rapid and simple LC–MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity
P2860
Q31011412-1FBB8B60-6537-4DE9-A263-3FFF2E0F89C8Q35003666-40FF9290-51F4-47A4-83A0-0E463D569BFBQ35086229-72D7FB81-B796-402C-902D-3B3B7CC01405Q36254435-344157F1-F026-42AC-B97F-88041E901015Q36538551-CB587AF8-0D6A-4C5D-ABDB-B62EEBE9131DQ36642463-ABC5B502-935F-4646-8D2F-4468C64FB170Q36927353-F43C2EDB-C19B-43B5-8416-6F20B0086FD7Q37079954-C40998AD-4E50-4B49-B43D-9BB6CCCF709FQ37979866-25D43DAD-AF5F-433A-BAA3-4A6ADFD8C72FQ38779550-54087753-EEF3-4EE1-A7DA-65A6B1336E2BQ39040900-14047EAC-240E-4045-A94C-F77E89345042Q40330877-58B88E70-9928-4010-9D74-C639C410E173Q41834120-97924F8D-635C-46A3-AEC3-1E405929C098Q42063808-E0E85A71-B9F4-410B-AA48-AC15C0501D49Q42282507-2A578487-D32D-4077-9B4E-3D29C369E033Q42712667-3522C283-A219-4695-9CEC-876990F22B43Q42978371-9AB9CF97-A971-48EB-B480-5CA9533188FEQ43144692-2E5375DB-42C0-43AC-ADCE-549F4FBF93D2Q44394691-183D4E75-B9E5-4D21-A10E-2E41D0C9D2DEQ46850739-3E43C694-61C0-4C6C-9F21-3F289806B5C0Q46908040-BC91A5EA-B223-43EE-A91D-105040896EBCQ47622129-E1094BD5-4F86-4DFE-AF82-F955A4718A36Q47692758-B0AA9258-36FB-4BAB-8BB7-CE79DA46F59CQ47947039-E3FAA1EC-2154-40E3-824D-F8519AB3C322Q48194386-AC36B3A0-DDC4-4961-8665-5A064C12461CQ48234146-9EDB036F-4D3B-4506-BC76-01FD83C2D905Q50095668-09FFF2A8-5A64-4761-93E0-35FCE19A5831Q57585643-DCD4EE75-CA65-4501-84C6-CFC207D9A788
P2860
"Cocktail" approaches and strategies in drug development: valuable tool or flawed science?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
"Cocktail" approaches and stra ...... luable tool or flawed science?
@ast
"Cocktail" approaches and stra ...... luable tool or flawed science?
@en
type
label
"Cocktail" approaches and stra ...... luable tool or flawed science?
@ast
"Cocktail" approaches and stra ...... luable tool or flawed science?
@en
prefLabel
"Cocktail" approaches and stra ...... luable tool or flawed science?
@ast
"Cocktail" approaches and stra ...... luable tool or flawed science?
@en
P2093
P2860
P356
P1476
"Cocktail" approaches and stra ...... luable tool or flawed science?
@en
P2093
Honghui Zhou
James F McLeod
P2860
P304
P356
10.1177/0091270003261333
P577
2004-02-01T00:00:00Z